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Abstract
Background Experimental and epidemiological studies
have demonstrated that urinary angiotensinogen (AGT) is
a novel biomarker for the intrarenal activity of the renin–
angiotensin system in hypertension (HT). Several large-
scale epidemiological studies have shown that an elevated
serum uric acid (SUA) level is associated with HT. The aim
of our study was to assess urinary AGT excretion and its
correlation with SUA level, the lipid profile, and the body
mass index (BMI) Z-score in hypertensive adolescents.
Methods Participants were divided into two groups: (1) the
group with confirmed HT consisting of 55 subjects with
primary HT and (2) the reference (R) group consisting of
33 subjects with white-coat HT. A commercial enzyme-
linked immunosorbent assay (ELISA) kit was used to deter-
mine urinary AGT concentration.
Results The urinary AGT/creatinine (cr.) ratio in subjects in
the HT group was significantly higher than that in the
reference group (p<0.01) and showed a strong positive
correlation with SUA (r=0.47, p<0.01). The relationship
between the AGT/cr. ratio and SUA levels after controlling
for age, gender and BMI Z-score continued to show a
significant association.
Conclusions The most obvious finding to emerge from this
study is that in adolescents with primary HT, the increased
urinary excretion of AGT correlated with hyperuricemia,
although large, multicenter studies are needed to confirm
this observation.
Keywords Adolescents . Urinary angiotensinogen .
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Introduction
Epidemiological and experimental data suggest that uric
acid could play a contributory role in the pathogenesis of
elevated blood pressure [1–4]. Feig et al. [5] reported that an
increased uric acid level of >5.5 mg/dL in 90 % of adoles-
cents with newly diagnosed primary hypertension (HT).
Saito et al. [6] confirmed that the renin–angiotensin system
(RAS) is also strongly related to elevated serum uric acid
(SUA) levels in hypertensive subjects. These authors found
that uric acid stimulated proliferation, angiotensin II produc-
tion and oxidative stress in vascular smooth muscle cells
(VSMCs) through the tissue RAS.
In recent years, the role of the intrarenal RAS in the
pathophysiology of both HT and renal injury has become a
focus of interest to researchers. Considerable attention has
been paid to the significance of the local/tissue RAS in differ-
ent tissues, including the brain, heart, adrenal glands, vascu-
lature and kidneys [7–13]. Urinary angiotensin II is unstable
and, therefore, cannot be used as a reliablemarker of intrarenal
RAS activity in clinical studies. Experimental studies have
demonstrated that angiotensinogen (AGT) levels in renal tis-
sues reflect the activity of the intrarenal RAS [12–15].
Katsurada et al. [16] recently developed a sandwich
enzyme-linked immunosorbent assay (ELISA) system to
directly measure urinary human AGT levels. Urinary AGT
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levels have been shown to be highly correlated with
intrarenal AGT and angiotensin II levels. Consequently,
urinary AGT concentration has been suggested as a reliable
marker for intrarenal RAS activity [17–19].
The aim of this study was to assess urinary AGT excretion
in hypertensive adolescents and to evaluate its correlation with
SUA, the lipid profile and body mass index (BMI) Z-score.
Patients and methods
This was a prospective cohort study of hypertensive adoles-
cents. The study included 88 subjects (33 girls, 55 boys)
aged 11–18 years who were referred to our unit (Department
of Pediatrics and Nephrology, The Medical University of
Białystok, Poland) between May 2010 and September 2011
to confirm or rule out the diagnosis of HT. The majority of
patients were referred by general practitioners who had
identified elevated blood pressure (BP) in the patient. We
divided the adolescents into two groups based on ambula-
tory blood pressure monitoring (ABPM): (1) a hypertensive
group (HT group) consisting of patients with confirmed
primary HT; (2) a reference (R) group consisting of patients
with white-coat HT. In addition, a group of adolescents with
HT was subsequently divided into two subgroups: (1) HT
HU(+) consisting of patients with HT accompanied by hy-
peruricemia; (2) HT HU(−), i.e. subjects with HT and nor-
mal SUA levels.
The study group (HT) consisted of 55 hypertensive sub-
jects [43 with hyperuricemia (SUA level of ≥5.5 mg/ dL)
and 12 with a SUA level of <5.5 mg/dL].
Inclusion criteria were an age of 11–18 years, primary
arterial HP [verified byABPM asmean daytime and nighttime
systolic BP (SBP) levels of ≥95th percentile for age, sex and
height, and a load SBP or DBP of >30 % [20], normal clinical
examination, renal ultrasound findings, normal electrocardio-
gram findings, normal levels of thyroid-stimulating hormone,
and creatinine (cr.) and urinalysis within the normal range.
Exclusion criteria were heart failure, diabetesmellitus, renal or
hepatic dysfunction, hematological disease, systemic inflam-
matory conditions, autoimmune diseases, secondary forms of
hypertension, girls treated with contraceptive pills, subjects
treated with hypertensive agents and medications known to
affect SUA levels and BP values.
The reference group consisted of 33 subjects in whom HT
was excluded at the moment of examination on the basis of
ABPM (mean daytime and nighttime SBP and DBP levels of
<90th percentile for age, sex and height and a load SBP and
DBP of <25%). The participants were term-born, with normal
birth weight, and were not receiving any medication at the
time of the examination. The blood and urine test results of
subjects in the reference group fell within the normal range.
The family history of adolescents classified in this group did
not reveal HT or other cardiovascular diseases. The medical
history was negative for both diabetes and gout.
The protocol was approved by the Bioethics Committee
of The Medical University of Białystok in accordance with
the Declaration of Helsinki. Informed consent was obtained
from parents of all participants and children older than
16 years of age.
For all subjects, careful clinical histories were taken and
physical examinations were performed. Body weight and
height were measured using a balance beam scale and pedi-
atric wall-mounted stadiometer, and BMI was calculated as
weight (in kilograms) divided by the square of height (me-
ters squared). BMI Z-scores, reflecting the standard devia-
tion score (SDS) for the age and gender appropriate BMI
distribution, were calculated using the formula: BMI Z-
scores = (50 percentile for age and gender/1/2 × (50 percen-
tile – 3 percentile for age and gender).
After 12 h of overnight fasting, urine and blood samples
were taken for the measurement of urinary AGTconcentration
and 24-h microalbuminuria, plasma renin activity, plasma
aldosterone level, C-reactive protein, basal glucose level, lipid
profile and serum creatinine, urea and SUA levels and mor-
phology of peripheral blood. The urinary AGT concentration
was measured using a commercially available ELISA kit
(USCN Life Science Inc., Houston, TX) according to the
manufacturer’s instructions. In brief, a monoclonal antibody
specific for AGTwas used to detect AGT in the urine samples.
Horseradish peroxidase-conjugated streptavidin was added,
followed by a color-forming peroxidase substrate containing
tetramethylbenzidine. The color was then measured at 450 nm
by a microtiter plate reader and compared with a standard
curve. Urinary AGT levels were expressed in nanograms per
milliliter. Urinary creatinine concentration was used to normal-
ize the AGT measurements to account for the influence of
urinary dilution on its concentration. The urinary levels of
creatinine were analyzed with Jaffé’s method. The AGT levels
were expressed as the urinary AGT/cr. ratio in nanograms per
milligram creatinine. Plasma renin activity and plasma aldo-
sterone concentrations were measured with commercially
ELISA kits using monoclonal antibodies (R&D Systems, Min-
neapolis, MN). Serum creatinine was determined by the Jaffé
reaction, and uric acid was measured using a Hitachi apparatus
(Hitachi, Chiyoda, Japan). The morphology of the peripheral
blood were assessed on a Coulter analyzer MAXM (Beckman
Coulter, Brea, CA). Serum cholesterol, high-density lipopro-
tein (HDL)-cholesterol and triglycerides were determined by
the enzymatic method using a Hitachi model 912 apparatus.
Serum glucose was measured with the Integra 800 ana-
lyzer (Roche Diagnostics, Mannheim, Germany). The 24-h
urinary albumin excretion rate (UAER) was analyzed by a
radioimmunoassay method. Albuminuria was considered as a
24-h UAER of >30 mg/24 h. Micro- and macroalbuminuria
were defined as 24-h UAER values of 30–300 mg/24 h and
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>300 mg/24 h, respectively. The estimated glomerular filtra-
tion rate (eGFR) was calculated from the Schwartz formula:
eGFR = k × G (cm)/ Lcr. (mg/dL), where k is the age-
dependent coefficient (0.55 in boys aged <12 years and girls
of any age, 0.70 in boys aged >12 years), G is growth and Lcr.
is the level of creatinine in the serum.
ABPM was performed using the SpaceLabs Medical
oscillometric blood pressure monitor (SpaceLab, Redwood,
WA). The monitors were programmed to measure BP every
15 min during daytime (800–2200 hours) and every 30 min
during nighttime (2200–8.00 hours); however, the periods were
corrected according to the subjects’ diaries. Recording started
between 8 and 9 a.m. and lasted for 24 h. Recordings with a
minimum 80 % of measurements and without breaks longer
than 2 h were considered to be sufficient for analysis. Themean
SBP and DBP were calculated separately for the 24-h period
and for the awake and asleep periods. Also analyzed were the
load systolic (LSBP) and diastolic (LDBP) BP during the day
and night. HT on the basis of ABPM was defined as the mean
daytime or nighttime SBP or DBP of ≥95th percentile and
LSBP or LDBP daytime or nighttime levels of >30 % [20].
The values were adjusted by gender and body height according
to the reference values provided by Wühl et al. [21]. Each
subject or his parent was asked to record the bedtime and time
of awakening. After 24 h, the cuff and monitor were removed,
and the data downloaded using the manufacturer’s software.
Statistical methods
Data analysis was performed using the computer program
Statistica 10.0 PL (StatSoft, Tulsa, IK). Discrete variables
were expressed as counts (percentage), whereas continuous
variables were expressed as the median and range, unless
stated otherwise. The two groups were compared using the
chi-square and Fisher exact tests for categorical variables
and the t test for continuous variables for normally distrib-
uted data and the Mann–Whitney test for the data distributed
not normally. Multiple linear regression analyses were
performed, including the AGT/cr ratio as dependent vari-
able, with serum levels of total cholesterol, triglycerides,
creatinine, uric acid, microalbuminuria, BMI Z-scores con-
sidered to be independent variables. Correlations between
AGT/cr and other variables (clinical and laboratory param-
eters) were evaluated using standard methods, such as the
Pearson’s or Spearman’s test accordingly. The value of p<
0.05 was considered to be statistically significant.
Results
The demographic, clinical and ambulatory BP data for each
group are summarized in Tables 1 and 2. The ABPM and
laboratory results were successfully collected from 88 ado-
lescents. Of these 88 subjects, 55 were HT and 33 had
white-coat HT (reference group). The effect size between
the hypertensive and reference groups was: 0.925326 −
power test 96 %. The median age did not differ between
groups. Males were more frequently affected with HT than
females, which is consistent with the available reports in the
area [22]. In the group with HT, 46 (83.6 %) were males and
nine (16.4 %) were females, whereas more girls (n=24,
72.7 %) than boys (n=9, 27.3 %) were found in the reference
group.
Table 1 Anthropometric, clinical and metabolic characteristics of subjects enrolled in the studya
Anthropometric, clinical
and metabolic characteristics
Reference group (n=33) Hypertensive group (n=55) p
Age (years) 16 (12–18) 17 (11–18) NS
BMI Z-score −0.03 (−1.62 to 3.83) 2.12 (−1.11 to 9.48) <0.01
Creatinine (mg/dL) 0.63 (0.37–0.89) 0.84 (0.48–1.13) <0.01
Uric acid (mg/dL) 4.6 (2.19–5.48) 6.49 (3.26–8.89) <0.01
Urea (mg/dL) 22 (14–35) 26 (12–57) <0.05
Triglycerides (mg/dL) 78 (56–134) 104 (32–238) <0.05
Urine creatinine (mg/dL) 0.91 (0.21–2.06) 1.44 (0.44–18.87) <0.01
eGFR (ml/ min/ 1.73 m2) 154.4 (103.9–265.26) 145.6 (113.9–233.3) <0.05
Renin activity (pg/mL) 18.45 (7.24–38.34) 25.15 (7–75.14) <0.01
Aldosterone (pg/mL) 2,872.7 (1,032.3–5972.2) 3,790.9 (238.8–9361.9) <0.01
AGT/cr. (ng/mg cr.) 0 (0–0.44) 0.17 (0–2.28) <0.01
BMI, Body mass index; eGFR, estimated glomerular filtration rate; AGT, angiotensin; cr., creatinine; NS, not significant
Data are presented as the median with the 95 % confidence interval (CI) in parenthesis
a Adolescents enrolled in the study were divided into two groups based on ambulatory blood pressure monitoring (ABPM): a hypertensive (HT)
group consisting of patients with confirmed primary HT and a reference ®) group consisting of patients with white-coat hypertension
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The body height, weight and BMI of HT adolescents
were higher compared to those in the reference group (p<
0.01). The median BMI Z-score in the HT group was 2.12
(range −1.11 to 9.48) and was higher than the median of the
reference group (p<0.01). Thirty-seven subjects (67.3 %)
from the HT group were classified as overweight or obese.
From the data in Fig. 1, it is apparent that the AGT/cr. ratio
was significantly increased in the subjects in the HT group in
comparison to the healthy controls. Similar significant differ-
ences were found in plasma renin activity, plasma aldosterone
level, SUA level, creatinine, urea, triglycerides and eGFR
between the HT subjects and the healthy reference subjects.
The median SUA concentration in HT subjects was sig-
nificantly higher than that in the subjects of the reference
group [6.49 (3.26–8.89) vs. 4.6 (2.19–5.48) mg/dL, respec-
tively; p<0.01]. The SUA level exceeded 5.5 mg/dL in
78.2 % of the subjects with HT.
We performed single regression and correlation analyses of
the AGT/cr. ratio according to clinical parameters (Fig. 2) and
found a significant nonlinear correlation between the urine
AGT/cr. ratio and SUA level (r=0.508, p<0.01). Additional-
ly, the urine AGT/cr. ratio was positively correlated with
height (r=0.32, p<0.01), body weight (r=0.34, p<0.01),
BMI Z-score (r=0.24, p<0.05) and triglyceride levels (r=
0.29, p<0.05). In a subsequent analysis we checked the re-
lationships between the AGT/cr. ratio and plasma renin activ-
ity and plasma aldosterone level. In the subjects in the HT
group, the AGT/cr. ratio correlated positively with plasma
aldosterone level (r=0.40, p<0.01) and plasma renin activity
(r=0.30, p<0.05); in contrast, in the reference group we did
not find any statistically significant correlation between these
parameters.
Because of the known effects of gender, age and param-
eters of physical development differences on SUA, we
performed multivariable linear regression to control for gen-
der, age, BMI Z-score and serum creatinine, triglyceride and
cholesterol levels. We selected statistically significant ex-
planatory variables such that the sum of squared residuals
would be minimal in the model. As a result gender, BMI Z-
score and serum creatinine level were excluded (p=0.68, p=
0.65, p=0.71, respectively). The model with the remaining
four parameters (SUA, triglycerides, cholesterol and age)
accounted for more than 41 % of the variations in the
AGT/cr. ratio (r2=0.412, p<0.001 for the model).
The results of the regression analysis of the AGT/cr. ratio
and SUA are summarized in Table 3.
The relationship between AGT/cr. levels and SUA levels
after controlling for age, gender and BMI Z-score continued
Table 2 Ambulatory blood
pressure data
D, day; N, night; L, load; SBD,
systolic blood pressure; DBP,
diastolic blood pressure; R,
reference group; HT, hyperten-
sive group (examined group)
Data are presented as the median
with the 5 % CI in parenthesis
ABPM parameters Reference group Hypertensive group p
Mean SBP/24 h (mmHg) 116 (105–126) 132 (115–156) <0.01
Mean DBP/24 h (mmHg) 66 (54–77) 72 (58–93) <0.01
LSBP (%) D 19 (0–25) 67.2 (3,2–100) <0.01
LSBP (%) N 14 (0–20) 33.3 (0–100) <0.01
LDBP (%) D 6.6 (0–25) 16.2 (0–85,7) <0.05
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Fig. 1 Comparison of angiotensin/creatinine (AGT/cr.) ratio between
the hypertensive (HT) subjects with confirmed primary HT and the
reference (R) subjects with white-coat hypertension





























Fig. 2 Exponential regression analysis demonstrating the relationship
between the angiotensin/creatinine (AGT/cr). ratio and serum creati-
nine, urea and uric acid (SUA) in all subjects
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to show a significant association. Based on the 24-h ABPM
results, all ABPM parameters, except for nighttime DBP
load, were significantly higher in adolescents with primary
HT than in those in the reference group.
We also analyzed the relationship between AGT/cr. and the
parameters derived from ABPM. We found a positive correla-
tion between AGT/cr. and mean SBP/24 h (r=0.24, p<0.05),
AGT/cr. and mean SBP during the daytime (r=0.27, p<0.05)
and AGT/cr. and daytime SBP loads (r=0.31, p<0.05).
Further statistical tests revealed a significant difference be-
tween urine AGT levels in subjects with HTand hyperuricemia
[HU(+)] and subjects with HT and normouricemia [HU(−);
median 0.2 (0.0–3.27) vs. 0.13 (0.0–0.3), respectively; p=
0.002)]. However, the significance was lost after the correction
for creatinine. This result may possibly be explained by the
lower number of subjects in the normouricemia group.
In the HU(+) group the AGT/cr. ratio was positively
correlated with plasma renin activity (r=0.35, p<0.05) and
plasma aldosterone level (r=0.39, p<0.05).
Discussion
In this cross-sectional study, the AGT/cr. ratio was signifi-
cantly higher in hypertensive adolescents than in teenagers
in whom diagnosis of HTwas not confirmed in 24-h ABPM
(reference group—white-coat HT). Other important findings
were positive correlations between AGT/cr. and height,
body weight, BMI, SUA and triglyceride levels. It is inter-
esting to note that the relationship between AGT/cr. levels
and SUA levels after controlling for age, gender and BMI Z-
score continued to a show significant association. The mul-
tivariable linear regression model that included SUA, tri-
glycerides, cholesterol and age accounted for more than
41 % of the variations in the AGT/cr. ratio.
To the best of our knowledge this is the first clinical study
of the association between urinary AGT level and hyperuri-
cemia in children and adolescents.
The prevalence of HT is increasing among young people
worldwide. One of the important metabolic abnormalities in
children and adolescents with primary HT appears to be
elevated SUA levels. Many large epidemiologic studies
have demonstrated that an elevated SUA level is associated
with HT [4, 23–26]. However, controversy still remains on
whether uric acid is an independent predictor, a mediator or
just a marker of the development of HT. The increased uric
acid level has been reported to induce HT by activating the
RAS and up-regulating proinflammatory mediators in
VSMCs [27, 28]. A study carried out in a large, nationally
representative sample of 6,036 U.S. adolescents (age range
12–17 years) has shown that SUA is associated with elevat-
ed BP [29]. Furthermore, participants with a uric acid level
of ≥5.5 mg/dL had a twofold higher odds ratio of having
elevated BP compared to those with a uric acid level of
≤5.5 mg/dL.
Corry et al. [30] reported that uric acid stimulated the
major components of the vascular RAS, including the stim-
ulation of both AGT and angiotensin II production. Recent
attention has focused on findings that the proximal
intratubular concentrations of angiotensin I and II are much
greater than their corresponding plasma concentrations,
which emphasizes the role of the local/tissue RAS in spe-
cific tissues [31, 32]. Also, the finding that there is a very
high formation of angiotensin I following the incubation of
proximal tubular fluid with excessive renin indicates a very
high AGT substrate availability in this segment [31, 33].
Kobori et al. [17, 18] reported that urinary AGT excretion
provides a specific index of the intrarenal RAS status in
angiotensin II-dependent hypertensive rats. They also
showed that the enhanced production of urinary AGT is
not a nonspecific consequence of proteinuria. The results
of another study demonstrated that the infusion of human
AGT into hypertensive and normotensive rats did not result
in its presence in the urine, suggesting that circulating AGT
is not a source of urinary AGT [18]. van den Heuvel et al.
suggested that the urinary AGT level reflects both renal
dysfunction and the beneficial effects of the RAS blockade
[34]. Contrary to expectations, in our study we found a
statistically significant association between the urine
AGT/cr. ratio and systemic activation of RAS in hyperten-
sive patients; however, we only measured plasma aldoste-
rone and plasma renin activity, but not plasma AGT. Our
results may be supported by those of Kobori et al. [19] who
showed a significant reduction of the AGT/cr. ratio in pa-
tients with HT treated with RAS blockers. These data sug-
gest that the efficacy of the RAS blockade to reduce the
intrarenal RAS activity can be assessed by measurements of
urinary AGT excretion [19]. In the reference group we did
not find statistically significant correlations between these
parameters.
Yamamoto et al. reported a lack of significant correlation
between urinary and plasma AGT levels [35].
It is plausible to consider that plasma AGT cannot easily
filter across the glomerular membrane because of its size
[12]. In light of this fact it is unlikely that most of the
increased urinary AGT in hypertensive patients with slight
Table 3 Multivariate regression analysis of angiotensin/creatinine
(AGT/cr). ratio and serum uric acid
Clinical parameters Standardized β Standard error p
Uric acid (mg/dL) 0.204 0.139 0.04
Triglycerides (mg/ dL) 0.413 0.170 0.02
Cholesterol (mg/dL) −0.632 0.162 <0.001
Age (years) −0.344 0.129 0.01
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proteinuria originates from the circulation. However, the
possible contribution of derangement of glomerular perme-
ability, which could result from progressive renal fibrosis
due to the increased urinary AGT level, cannot be ruled out.
Previous methods for determining the concentration of
AGT in the urine were difficult to perform and prone to
generate significant methodological errors. In 2007,
Katsurada et al. developed a sandwich ELISA system to
directly and sensitively measure urinary human AGT [16].
There are limited data on AGT excretion in the literature.
Kobori et al. described similar AGT excretion values as
those reported by us in patients with chronic kidney disease
[36]. The AGT/cr. ratio in patients with type 2 diabetic
nephropathy or with membranous nephropathy were much
higher than the overall average levels in patients with chron-
ic kidney disease [36]. Importantly, Mezzano et al. reported
that the activation of the intrarenal RAS participates in the
progression of renal injury in patients with diabetic nephrop-
athy [37] and membranous nephropathy [38]. In contrast,
Kobori et al. [36] demonstrated the AGT/cr. levels in their
patients with minimal change disease were similar to those
in the control group, even though the patients with minimal
change had severe proteinuria. The above data and also the
results from a number animal studies on HT clearly indicate
that augmented AGT excretion is not simply a nonspecific
consequence of proteinuria. In our study, we found no
correlation between urinary AGT concentration and albu-
minuria levels. Similar observations have been reported by
Lantelme et al. [39] in adult patients with HT.
In our study the urinary excretion of AGT correlated with
some components of metabolic syndrome, such as obesity,
hyperuricemia and serum triglyceride levels.
The statistical analysis included multivariate analysis
with the presentation of the independent factors associated
with an increased urine AGT/cr. ratio. The multivariable
linear regression model excluded the influence of gender,
BMI Z-score and serum creatinine level, but included the
parameter triglycerides, which might have a positive impact
on the urine AGT/cr. ratio. The impact of serum cholesterol
was significant, but negative, so should not be considered.
However, more research on this topic needs to be undertak-
en before the association between the AGT/cr. ratio and
metabolic syndrome is more clearly understood.
In summary, although our investigations into this area are
still ongoing, our preliminary results allow us to draw the
following conclusions: (1) children and adolescents with
primary HT have an increased urinary excretion of AGT;
(2) hyperuricemia appears to be a factor which significantly
increases the excretion of AGT in adolescents with primary
HT, although large, multicenter studies are needed to con-
firm this observation. Finally, a number of important limi-
tations need to be considered. First, the reference group was
not a group of healthy teenagers, but a group of patients in
whom hypertension was not confirmed in 24-h ABPM;
consequently these subjects are considered to belong to the
white-coat HT group. Secondly, the two study groups clear-
ly differed: the hypertensive group consisted of adolescent
males mainly with a high BMI Z-score and the reference
group included slim females with white-coat HT. However,
as the multivariate analysis was able to show that neither
gender nor the BMI Z-score influenced the relationship
between the AGT/cr. ratio and SUA levels.
However, despite the limitations of this study, we believe
that the unique position of AGT in the RAS and its function
underlines the importance of this protein as attractive target
in developing new effective strategies for the management
of many diseases, particularly HT, atherosclerosis and obe-
sity. At present, there is still no information in the literature
on the role of AGT produced in local tissues in the patho-
physiology of HT, nor on the correlation of AGT produced
in situ with the circulating pool of AGT.
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